Meeting
2023 ASCO Annual Meeting
Biomarker-driven prospective clinical trial in renal cell carcinoma: Developing machine learning models to allocate patients to treatment arms using RNA sequencing.
Authors
Anupama Reddy
Vindhya Data Science, Durham, NC
Anupama Reddy , Scott Mattox Haake , Katy Beckermann , Alex Nesta , Adnan Derti , Wendy Kimryn Rathmell , Nanguneri Nirmala , Brian I. Rini
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Biologic Correlates
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4525)
DOI
10.1200/JCO.2023.41.16_suppl.4525
Abstract #
4525
Poster Bd #
17
Abstract Disclosures
Similar Posters
First Author: Scott Mattox Haake
Poster
2023 ASCO Genitourinary Cancers Symposium
Optimal treatment by invoking biologic clusters in renal cell carcinoma (OPTIC RCC).
First Author: Yu-Wei Chen
Poster
2023 ASCO Breakthrough
Predicting response of gemcitabine plus cisplatin chemotherapy using RNA sequencing in patients with advanced urothelial carcinoma.
First Author: Kwonoh Park
Poster
2023 ASCO Annual Meeting
Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC).
First Author: Katy Beckermann